Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
By R. Finn, S. Qin, M. Ikeda, Peter R. Galle, Michel Ducreux, Tae-You Kim, M. Kudo, V. Breder, P. Merle, A. Kaseb and 11 more. New England Journal of Medicine, 2020
5,608 citations recorded by the source corpus.
BACKGROUND The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma. METHODS In a global, open-label, phase 3 trial, patients with unresectable hepatocellular carcinoma who had not previously received systemic treatment were randomly assigned in a 2:1 ratio to receive either atezolizumab plus bevacizumab or sorafenib until unacceptable toxic effects occurred or there was a loss of clinical benefit. The coprimary end points were overall survival and progression-free survival in the intention-to-treat population, as assessed at an independent review facility according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1). RESULTS The intention-to-treat population included 336 patients in the atezolizumab-bevacizumab group and 165 patients in the sorafenib group. At the time of the primary analysis (August 29, 2019), the hazard ratio for death with atezolizumab-bevacizumab as compared with sorafenib was 0.58 (95% confidence interval [CI], 0.42 to 0.79; P<0.001). Overall survival at 12 months was 67.2% (95% CI, 61.3 to 73.1) with atezolizumab-bevacizumab and 54.6% (95% CI, 45.2 to 64.0) with sorafenib. Median progression-free survival was 6.8 months (95% CI, 5.7 to 8.3) and 4.3 months (95% CI, 4.0 to 5.6) in the respective groups (hazard ratio for disease progression or death, 0.59; 95% CI, 0.47 to 0.76; P<0.001). Grade 3 or 4 adverse events occurred in 56.5% of 329 patients who received at least one dose of atezolizumab-bevacizumab and in 55.1% of 156 patients who received at least one dose of sorafenib. Grade 3 or 4 hypertension occurred in 15.2% of patients in the atezolizumab-bevacizumab group; however, other high-grade toxic effects were infrequent. CONCLUSIONS In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT03434379.).
Subfields: Hepatology, Pathology and Forensic Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/b30ec8954964a10fdc549e11fe5c8303657a82c8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
In Pathology and Forensic Medicine
In Surgery
Citations in the corpus
- Advances in immunotherapy for hepatocellular carcinoma (2021, background): “I.M. receives funding from MINECO SAF2014-52361-R and SAF 2017- 83267-C2-1R; Worldwide Cancer Research Grant (15-1146); the Asociacion Española Contra el Cancer (AECC) Foundation under grant GCB15152947MELE; and the European Union’s Horizon 2020 Program (grant agreement no. 635122 PROCROP).”
- AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023, positive): “…PD-L1, plus bevacizumab, a monoclonal antibody targeting VEGF, as the preferred first-line treatment option for patients with advanced HCC. [312] The median OS of 19.2 months with atezolizumab plus bevacizumab is the longest median OS of any first-line treatment for advanced-stage HCC to…”
- Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022, background): “Then, in 2020, the FDA approved atezolizumab combined with bevacizumab for advanced HCC based on the data of IMbrave150 [111].”
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma (2020, neutral): “Diarrhea 35 (35) 19 (19) 11 (11) 5 (5) Fatigue 30 (30) 12 (12) 14 (14) 4 (4) Decreased appetite 28 (28) 12 (12) 16 (16) 0”
- Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy (2023, background): “atezolizumab plus bevacizumab and durvalumab plus tremelimumab compared with camrelizumab plus rivoceranib (grade 3–4 in 43% and 26% versus 81% of patients, respectively) 177,178,186,234 .”
- Cancer statistics, 2023 (2023, background): “Checkpoint inhibitors and targeted therapies are also showing promise in difficult‐to‐treat advanced renal cell carcinoma.(86) TAB L E 6 Trends in 5‐year relative survival rates (%) by race, United States, 1975–2019”